8-K: Celcuity's REVTORPYK Now Commercially Available for Breast Cancer

Celcuity Inc. announces the commercial availability of REVTORPYK (gedatolisib) in the U.S. for eligible patients with advanced breast cancer.

Summary

• Celcuity Inc. has announced that its drug REVTORPYK (gedatolisib) is now commercially available in the United States.
• The drug is indicated for eligible patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer (ABC).
• Patients must have a PIK3CA wild-type status and have progressed after at least one line of endocrine therapy in the metastatic setting.
• REVTORPYK was approved by the FDA on July 14, 2026, in combination with palbociclib and fulvestrant (triplet) or with fulvestrant alone (doublet).
• The company has launched a patient support program, REVTORPYK Support Services, to assist with insurance coverage, access, reimbursement, and financial assistance.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, marking the commercial availability of a new drug for a significant unmet need in breast cancer treatment.

Positives

• Commercial availability of REVTORPYK in the U.S. for a specific breast cancer patient population.
• REVTORPYK is the first and only FDA-approved therapy that inhibits all class I PI3K isoforms and mTOR complexes.
• In the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial, REVTORPYK triplet and doublet reduced the risk of disease progression or death by 76% and 67%, respectively, compared to fulvestrant.
• A comprehensive patient support program is available to assist with access, reimbursement, and financial aid.
• Celcuity is pursuing a supplemental New Drug Application for REVTORPYK to treat patients with PIK3CA mutated advanced breast cancer.

Negatives

• REVTORPYK can cause severe stomatitis (72% incidence in triplet, 58% in doublet), rash (30% in triplet, 40% in doublet), and hyperglycemia (46% in triplet, 57% in doublet).
• The drug carries a risk of embryo-fetal toxicity and advises against breastfeeding.
• The safety of REVTORPYK has not been established in patients with Type 1 or uncontrolled Type 2 diabetes mellitus.

Risks

• Potential for severe stomatitis, rash, and hyperglycemia requiring dose adjustments or discontinuation.
• Embryo-fetal toxicity necessitates effective contraception for patients of reproductive potential.
• The company faces risks related to ongoing clinical trials, FDA review of supplemental applications, and market acceptance of REVTORPYK.
• Competition from other therapies targeting the PI3K/AKT/mTOR pathway.

Future Outlook

Celcuity is pursuing a supplemental New Drug Application for REVTORPYK to treat patients with PIK3CA mutated advanced breast cancer, which could expand its potential patient population. The company also has ongoing clinical trials for other indications, including metastatic castration-resistant prostate cancer.

Management Comments

• "Our experienced commercial and medical affairs teams have been laying the groundwork for a successful launch with healthcare providers, payers, and patient advocacy partners since REVTORPYK was approved," said Brian Sullivan, CEO and co-founder of Celcuity.
• "Now that REVTORPYK is commercially available, we are focused on working with physicians to bring this new treatment option to patients living with HR+/HER2advanced breast cancer."
• "REVTORPYK demonstrated unprecedented clinical benefit in the pivotal VIKTORIA-1 study, and we believe, provides an important new therapeutic option to address this need. We are excited now to make this new therapy available to physicians and their patients," said Igor Gorbatchevsky, MD, Chief Medical Officer of Celcuity.

Industry Context

StockSavvy.ai notes that the commercialization of REVTORPYK addresses a critical need for targeted therapies in HR+/HER2advanced breast cancer, particularly for patients who have progressed on endocrine therapy and lack a PIK3CA mutation. This launch positions Celcuity within the competitive landscape of oncology drug development, where precision medicine and pathway-specific inhibitors are increasingly important.

Stakeholder Impact

• Shareholders: Potential for increased revenue and market share for Celcuity.
• Patients: Access to a new targeted therapy option for advanced breast cancer.
• Healthcare Providers: Availability of a new treatment to prescribe and manage.
• Payers: Need to establish reimbursement pathways for REVTORPYK.

Next Steps

• Focus on working with physicians to bring REVTORPYK to eligible patients.
• Continue to support patient access through the REVTORPYK Support Services program.
• Await potential approval of the supplemental New Drug Application for REVTORPYK in PIK3CA mutated advanced breast cancer.

Key Dates

Recommendation

The commercial launch of REVTORPYK is a significant milestone, but the stock's performance will depend on market adoption, sales figures, and the outcome of the supplemental NDA for PIK3CA mutated patients. While positive, it warrants a 'hold' to assess initial commercial performance and further clinical developments.

Keywords

REVTORPYK, gedatolisib, breast cancer, advanced breast cancer, HR+, HER2-, PIK3CA, PI3K inhibitor